Testing increasing doses of abemaciclib for early breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This study tests whether gradually increasing doses of a drug called abemaciclib, combined with hormone therapy, can safely treat early-stage breast cancer that is hormone-positive and HER2-negative. The goal is to find the best dose that works without causing too many side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old
- Your breast cancer is hormone-positive (ER and/or PR positive) and HER2-negative
- You have had breast surgery to remove the cancer
- You are willing to take abemaciclib plus hormone therapy for at least 12 weeks, starting with lower doses that gradually increase
- Your overall health is good enough for this treatment (ECOG score 0–1)
- Your liver, kidneys, and blood counts are healthy enough for this medication
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether women with early-stage HR+/HER2- breast cancer can safely take a higher dose of the drug abemaciclib (Verzenio) after surgery. The goal is to keep the treatment as strong as possible while managing side effects.
This study follows women taking abemaciclib (a targeted cancer drug) for early-stage hormone-receptor-positive breast cancer to understand how the treatment affects their quality of life and health outcomes. The goal is to improve care for people in this situation.
This trial tests if adding abemaciclib (a targeted pill) to standard chemotherapy before surgery can shrink HR+/HER2- breast cancer and allow less extensive surgery. It also aims to see if a genetic test (Oncotype DX) can help guide treatment decisions.
This trial tests whether the drug abemaciclib can help women with hormone receptor-positive, HER2-negative breast cancer who still have signs of cancer DNA in their blood after standard treatment. It aims to prevent a future return of the cancer.
This Phase 2 study tests whether abemaciclib combined with standard hormone (endocrine) therapy can better control metastatic breast cancer in people age 70 and older. It may help if your cancer has already grown despite prior hormone therapy and/or other cancer medicines.
This study looks at real-world safety and side effect management of abemaciclib combined with hormone therapy for patients with RH+, HER2- breast cancer. It aims to understand how well patients tolerate treatment outside of clinical trials.
Hear when a new HR+/HER2- Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.